BOLERO-2 is a phase III , double-blind , randomized international trial comparing EVE 10 mg/day plus EXE 25 mg/day versus placebo ( PBO ) + EXE 25 mg/day in postmenopausal women with HR ( + ) advanced breast cancer with prior exposure to NSAIs .